In a research report issued today, Cowen analyst Ritu Baral maintained an Outperform rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), while no price target was provided. The report comes as the company is expected to announce phase 3 data in Sickle Cell Crisis for its lead drug ‘188 EPIC (vepoloxamer) in the first quarter 2016.
Baral wrote, “We think ‘188 could benefit numerous pathologies in SCD, especially vaso-occlusive crises (VOC). We are cautiously optimistic for the current Ph3 EPIC trial in SCD VOC and believe if the study shows strong trends of clinical benefit, but misses statistical significance, the data could still support approval. We think the slight delay in enrollment completion from 4Q15 to 1Q16 is largely inconsequential, given the difficulty of enrolling SCD crises trials.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ritu Baral has a total average return of 21.4% and a 47.9% success rate. Baral has a 20.4% average return when recommending MSTX, and is ranked #102 out of 3737 analysts.
All the 3 analysts polled by TipRanks rate Mast Therapeutics stock a Buy. With a return potential of 397.7%, the stock’s consensus target price stands at $2.33.